The Europe Left Atrial Appendage (LAA) Closure Device Market would witness market growth of 18.6% CAGR during the forecast period (2022-2028).
The LAA is located near the apex of the upper left chamber of the heart. If the doctor recommends that blood clots in the LAA expose the patient to the risk for a stroke, they may be treated with blood thinners (anticoagulants) and other drugs that regulate their heartbeat. If these treatments are ineffective or patients are unable to tolerate them, the practitioner would suggest an LAA closure operation.
The treatment is effective because the left atrial appendage is sealed off. Ischemic stroke describes a stroke caused by a blood clot, especially one induced by atrial fibrillation (Afib). Ischemic strokes account for a significant proportion of all strokes among people all over the world. While LAA closure lessens the risk of cardiac blood clots, it is not a treatment for Afib. It neither stops the irregular or unpredictable pulse nor treats the underlying cause of Afib.
Effective therapy and management of Afib would depend on adhering to medical advice, including the use of any prescribed drugs or further treatments, as well as dietary and lifestyle modifications. There are several current devices and procedures for closing up the left atrial appendage. The medical team would review the different treatment choices with the patient and offer a recommendation based on their individual circumstances.
Atrial fibrillation is a very prevalent disease in several European countries. According to the European Society for Cardiology, it is the most prevalent cardiac rhythm disorder and accounts for approximately 0.28 to 2.6% of healthcare expenditures in European nations. Patients with atrial fibrillation above the age of 80 have an increased risk of stroke, therefore this demographic transition has major ramifications for the EU. Additionally, older people are more likely to have comorbidities associated with atrial fibrillation, such as heart failure or cognitive impairment. Thus, the rising prevalence of atrial fibrillation has bolstered the growth of the regional market.
The Germany market dominated the Europe Left Atrial Appendage (LAA) Closure Device Market by Country in 2021; thereby, achieving a market value of $270 million by 2028. The UK market is exhibiting a CAGR of 17.6% during (2022 - 2028). Additionally, The France market would showcase a CAGR of 19.5% during (2022 - 2028).
Based on Application, the market is segmented into Geospatial Mapping, Disaster Management, Energy & Resource Management, Surveillance & Monitoring, and Others. Based on End User, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Left Atrial Appendage (LAA) Closure Device Market will Hit $4 Billion by 2028, at a CAGR of 19.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
By End-use
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
